Archemix (United States)

Institution (Company)

Homepage ROR

Also Known As

Archemix (United States)

Publications

20K

Citations

Authors

Concepts

About

Archemix (United States) is a company institution in Cambridge, United States known for medicine, pharmacology, and inflammation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	81	9.1K
2	Engineering	3	23	2.1K
3	Natural Sciences	3	5	275
4	Health Sciences	2	6	322
5	Biochemistry	2	4	182

Archemix (United States)

Publications

20K

Citations

Page 1

	Year	Citations
Direct In Vitro Selection of a 2′-O-Methyl Aptamer to VEGF Paula E. Burmeister, Scott D. Lewis, Robert F. Silva, Chemistry & Biology AngiogenesisDevelopmental BiologyHuman GrowthGene Delivery2′-O-methyl Aptamer	2005	346
Pharmacokinetics and Biodistribution of Novel Aptamer Compositions Judith M. Healy, Scott D. Lewis, Markus Kurz, Pharmaceutical Research PharmacologyPharmaceutical ScienceNovel Aptamer CompositionsPharmaceutical Research	2004	287
Aptamer-based biosensor arrays for detection and quantification of biological macromolecules Thomas McCauley, Nobuko Hamaguchi, Martin Stanton Analytical Biochemistry EngineeringBioanalysisAptamer-based Biosensor ArraysBiomedical AnalysisAnalytical Chemistry	2003	265
Involvement of CD14, Toll-Like Receptors 2 and 4, and MyD88 in the Host Response to the Fungal Pathogen<i>Cryptococcus neoformans</i>In Vivo Lauren E. Yauch, Michael K. Mansour, Shmuel Shoham, Infection and Immunity	2004	181
Effect of CC Chemokine Receptor 2 CCR2 Blockade on Serum C-Reactive Protein in Individuals at Atherosclerotic Risk and With a Single Nucleotide Polymorphism of the Monocyte Chemoattractant Protein-1 Promoter Region Jim Gilbert, Julie Lekstrom-Himes, Debra D. Donaldson, The American Journal of Cardiology InflammationCcr2 BlockadeSingle Nucleotide PolymorphismCardiovascular DiseaseImmunology	2011	175
Sequential Loss of Tumor Vessel Pericytes and Endothelial Cells after Inhibition of Platelet-Derived Growth Factor B by Selective Aptamer AX102 Barbara Sennino, Beverly L. Falcón, Dilara McCauley, Cancer Research	2007	153
Inhibition of von Willebrand factor‐mediated platelet activation and thrombosis by the anti‐von Willebrand factor A1‐domain aptamer ARC1779 Daniel Duerschmied, Yahye Merhi, J.F. TANGUAY, Journal of Thrombosis and Haemostasis ThrombosisBlood PlateletVon WillebrandHematologyPharmacology	2009	152
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist Ailsa J. Frew, Ralph K. Lindemann, Ben P. Martin, Proceedings of the National Academy of Sciences	2008	148
Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor Emily K. Waters, Ryan M. Genga, M. C. Schwartz, Blood	2011	140
Inhibition of cell adhesion by anti–P-selectin aptamer: a new potential therapeutic agent for sickle cell disease Diana Gutsaeva, James B. Parkerson, Shobha Yerigenahally, Blood	2010	139

Page 1